ADMA Biologics, Inc. (ADMA) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Relay Therapeutics, Inc.

Syndax Pharmaceuticals, Inc.

ADMA Biologics, Inc.

Protagonist Therapeutics, Inc.

Prime Medicine, Inc.

Dianthus Therapeutics, Inc.

Immatics NV

Cogent Biosciences, Inc.

Rayzebio, Inc.

Replimune Group, Inc.

Pliant Therapeutics, Inc.

Why is ADMA Biologics, Inc. ?

Flat results in Jun 26

NET PROFIT(9M) At USD 132.53 MM has Grown at -24.38%
INTEREST COVERAGE RATIO(Q) Lowest at 1,583.7
INVENTORY TURNOVER RATIO(HY) Lowest at 0.84 times

With ROE of 31.34%, it has a very expensive valuation with a 4.62 Price to Book Value

Over the past year, while the stock has generated a return of -40.90%, its profits have fallen by -24.8%

Underperformed the market in the last 1 year

Even though the market (S&P 500) has generated returns of 22.36% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -40.90% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is ADMA Biologics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

ADMA Biologics, Inc.

-40.9%

-0.10

54.58%

S&P 500

22.36%

1.70

13.18%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

64.60%

EBIT Growth (5y)

37.69%

EBIT to Interest (avg)

0.77

Debt to EBITDA (avg)

0.83

Net Debt to Equity (avg)

0.01

Sales to Capital Employed (avg)

0.99

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

11.78%

ROE (avg)

14.07%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.62

EV to EBIT

11.43

EV to EBITDA

10.97

EV to Capital Employed

4.73

EV to Sales

4.29

PEG Ratio

Dividend Yield

ROCE (Latest)

41.35%

ROE (Latest)

31.34%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 136.72 MM

RAW MATERIAL COST(Y)

Fallen by -26.29% (YoY

CASH AND EQV(HY)

Highest at USD 274.17 MM

-11What is not working for the Company

NET PROFIT(9M)

At USD 132.53 MM has Grown at -24.38%

INTEREST COVERAGE RATIO(Q)

Lowest at 1,583.7

INVENTORY TURNOVER RATIO(HY)

Lowest at 0.84 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 4.13 times

INTEREST(Q)

Highest at USD 3.42 MM

Here's what is working for ADMA Biologics, Inc.

Operating Cash Flow

Highest at USD 136.72 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Cash and Eqv

Highest at USD 274.17 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by -26.29% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for ADMA Biologics, Inc.

Interest

At USD 3.42 MM has Grown at 63.05%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Interest Coverage Ratio

Lowest at 1,583.7

in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Net Profit

At USD 132.53 MM has Grown at -24.38%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Interest

Highest at USD 3.42 MM

in the last five periods and Increased by 63.05% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Inventory Turnover Ratio

Lowest at 0.84 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio

Lowest at 4.13 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio